Inflammation activation and resolution in human tendon disease.

Improved understanding of the role of inflammation in tendon disease is required to facilitate therapeutic target discovery. We studied supraspinatus tendons from patients experiencing pain before and after surgical subacromial decompression treatment. Tendons were classified as having early, interm...

पूर्ण विवरण

ग्रंथसूची विवरण
मुख्य लेखकों: Dakin, S, Martinez, F, Yapp, C, Wells, G, Oppermann, U, Dean, B, Smith, R, Wheway, K, Watkins, B, Roche, L, Carr, A
स्वरूप: Journal article
भाषा:English
प्रकाशित: American Association for the Advancement of Science 2015
_version_ 1826280174772027392
author Dakin, S
Martinez, F
Yapp, C
Wells, G
Oppermann, U
Dean, B
Smith, R
Wheway, K
Watkins, B
Roche, L
Carr, A
author_facet Dakin, S
Martinez, F
Yapp, C
Wells, G
Oppermann, U
Dean, B
Smith, R
Wheway, K
Watkins, B
Roche, L
Carr, A
author_sort Dakin, S
collection OXFORD
description Improved understanding of the role of inflammation in tendon disease is required to facilitate therapeutic target discovery. We studied supraspinatus tendons from patients experiencing pain before and after surgical subacromial decompression treatment. Tendons were classified as having early, intermediate, or advanced disease, and inflammation was characterized through activation of pathways mediated by interferon (IFN), nuclear factor κB (NF-κB), glucocorticoid receptor, and signal transducer and activator of transcription 6 (STAT-6). Inflammation signatures revealed expression of genes and proteins induced by IFN and NF-κB in early-stage disease and genes and proteins induced by STAT-6 and glucocorticoid receptor activation in advanced-stage disease. The proresolving proteins FPR2/ALX and ChemR23 were increased in early-stage disease compared to intermediate- to advanced-stage disease. Patients who were pain-free after treatment had tendons with increased expression of CD206 and ALOX15 mRNA compared to tendons from patients who continued to experience pain after treatment, suggesting that these genes and their pathways may moderate tendon pain. Stromal cells from diseased tendons cultured in vitro showed increased expression of NF-κB and IFN target genes after treatment with lipopolysaccharide or IFNγ compared to stromal cells derived from healthy tendons. We identified 15-epi lipoxin A4, a stable lipoxin isoform derived from aspirin treatment, as potentially beneficial in the resolution of tendon inflammation.
first_indexed 2024-03-07T00:09:45Z
format Journal article
id oxford-uuid:78d46969-1151-4a9b-93e7-0393f9a84cb1
institution University of Oxford
language English
last_indexed 2024-03-07T00:09:45Z
publishDate 2015
publisher American Association for the Advancement of Science
record_format dspace
spelling oxford-uuid:78d46969-1151-4a9b-93e7-0393f9a84cb12022-03-26T20:33:13ZInflammation activation and resolution in human tendon disease.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:78d46969-1151-4a9b-93e7-0393f9a84cb1EnglishSymplectic Elements at OxfordAmerican Association for the Advancement of Science2015Dakin, SMartinez, FYapp, CWells, GOppermann, UDean, BSmith, RWheway, KWatkins, BRoche, LCarr, AImproved understanding of the role of inflammation in tendon disease is required to facilitate therapeutic target discovery. We studied supraspinatus tendons from patients experiencing pain before and after surgical subacromial decompression treatment. Tendons were classified as having early, intermediate, or advanced disease, and inflammation was characterized through activation of pathways mediated by interferon (IFN), nuclear factor κB (NF-κB), glucocorticoid receptor, and signal transducer and activator of transcription 6 (STAT-6). Inflammation signatures revealed expression of genes and proteins induced by IFN and NF-κB in early-stage disease and genes and proteins induced by STAT-6 and glucocorticoid receptor activation in advanced-stage disease. The proresolving proteins FPR2/ALX and ChemR23 were increased in early-stage disease compared to intermediate- to advanced-stage disease. Patients who were pain-free after treatment had tendons with increased expression of CD206 and ALOX15 mRNA compared to tendons from patients who continued to experience pain after treatment, suggesting that these genes and their pathways may moderate tendon pain. Stromal cells from diseased tendons cultured in vitro showed increased expression of NF-κB and IFN target genes after treatment with lipopolysaccharide or IFNγ compared to stromal cells derived from healthy tendons. We identified 15-epi lipoxin A4, a stable lipoxin isoform derived from aspirin treatment, as potentially beneficial in the resolution of tendon inflammation.
spellingShingle Dakin, S
Martinez, F
Yapp, C
Wells, G
Oppermann, U
Dean, B
Smith, R
Wheway, K
Watkins, B
Roche, L
Carr, A
Inflammation activation and resolution in human tendon disease.
title Inflammation activation and resolution in human tendon disease.
title_full Inflammation activation and resolution in human tendon disease.
title_fullStr Inflammation activation and resolution in human tendon disease.
title_full_unstemmed Inflammation activation and resolution in human tendon disease.
title_short Inflammation activation and resolution in human tendon disease.
title_sort inflammation activation and resolution in human tendon disease
work_keys_str_mv AT dakins inflammationactivationandresolutioninhumantendondisease
AT martinezf inflammationactivationandresolutioninhumantendondisease
AT yappc inflammationactivationandresolutioninhumantendondisease
AT wellsg inflammationactivationandresolutioninhumantendondisease
AT oppermannu inflammationactivationandresolutioninhumantendondisease
AT deanb inflammationactivationandresolutioninhumantendondisease
AT smithr inflammationactivationandresolutioninhumantendondisease
AT whewayk inflammationactivationandresolutioninhumantendondisease
AT watkinsb inflammationactivationandresolutioninhumantendondisease
AT rochel inflammationactivationandresolutioninhumantendondisease
AT carra inflammationactivationandresolutioninhumantendondisease